AMP Capital Investors Ltd decreased its holdings in Pfizer Inc. (NYSE:PFE) by 3.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,193,895 shares of the biopharmaceutical company’s stock after selling 67,786 shares during the period. AMP Capital Investors Ltd’s holdings in Pfizer were worth $78,322,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in PFE. Shine Investment Advisory Services Inc. purchased a new stake in Pfizer in the second quarter worth $102,000. Mckinley Capital Management LLC Delaware purchased a new stake in Pfizer in the second quarter worth $103,000. Herndon Capital Management LLC purchased a new stake in Pfizer in the second quarter worth $120,000. Private Vista LLC increased its stake in Pfizer by 2,277.3% in the second quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 190,933 shares during the period. Finally, Lipe & Dalton increased its stake in Pfizer by 6.9% in the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 300 shares during the period. Institutional investors and hedge funds own 70.12% of the company’s stock.
Shares of Pfizer Inc. (NYSE PFE) opened at $35.74 on Friday. Pfizer Inc. has a 12-month low of $31.67 and a 12-month high of $39.43. The firm has a market capitalization of $213,040.00, a PE ratio of 10.15, a P/E/G ratio of 2.03 and a beta of 0.94. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. During the same quarter last year, the company earned $0.47 earnings per share. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.81%. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is presently 38.64%.
Pfizer announced that its Board of Directors has authorized a stock repurchase program on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its shares are undervalued.
PFE has been the topic of a number of recent analyst reports. Jefferies Group set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Thursday, October 26th. BMO Capital Markets set a $39.00 price target on Pfizer and gave the company a “buy” rating in a research note on Tuesday, October 31st. Berenberg Bank set a $36.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Tuesday, October 31st. UBS Group set a $38.00 price target on Pfizer and gave the company a “buy” rating in a research note on Wednesday, November 1st. Finally, Goldman Sachs Group set a $36.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $39.45.
In related news, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the sale, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: “AMP Capital Investors Ltd Sells 67,786 Shares of Pfizer Inc. (PFE)” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.thelincolnianonline.com/2018/02/23/amp-capital-investors-ltd-sells-67786-shares-of-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.